This content is machine translated From symptom to diagnosis Gynecomastia and Adipomastia The term ” gynecomastia ” refers to the enlargement of the mammary gland in men, which may be unilateral or bilateral. True gynecomastia, caused by an increase in glandular tissue,...…
View Post 7 min This content is machine translated Plastic surgery and reconstructive microsurgery for DFS Functional limb preservation between infection control, vascular medicine and resurfacing Diabetic foot syndrome (DFS) is one of the most serious and functionally significant complications of diabetes, with a high number of functionally relevant amputations. DFS is not to be understood...… CME-Test
View Post 12 min This content is machine translated SURPASS-CVOT Tirzepatide versus Dulaglutide in T2D with ASCVD GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that...…
View Post 13 min This content is machine translated What the latest studies on the entire EF spectrum mean for clinical practice Heart Failure – The 2026 Evidence Update Since the release of the 2021 ESC guidelines and the 2022 AHA/ACC/HFSA guidelines, research on heart failure has reached a remarkable level of intensity. Nonsteroidal mineralocorticoid receptor antagonists and incretin-based...…
View Post 5 min This content is machine translated CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes Approximately 30–40% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In “landmark” studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)...…
View Post 5 min This content is machine translated Mental Health with GLP-1 RAs Benefits of Semaglutide and Liraglutide GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity. Depression and anxiety disorders are common among people with diabetes and obesity, and both conditions are associated with...…
View Post 12 min This content is machine translated The Brain and the Motivation to Eat Why is it so hard to lose weight? Obesity is the most common chronic disease in Western societies, with serious metabolic, cardiovascular, and psychosocial consequences. The therapeutic landscape has changed fundamentally: new-generation GLP-1 agonists achieve weight loss that,...… CME-Test
View Post 12 min This content is machine translated Global Recommendation, Swissmedic Approval, and SL Limitation WHO Guidelines on GLP-1 for Obesity With the guideline published on December 1, 2025, the World Health Organization has, for the first time, issued a globally applicable recommendation on the pharmacological management of obesity in adults....…
View Post 18 min This content is machine translated From Risk Identification to Anti-Inflammatory Intervention Inflammation as a Treatment Goal in Its Own Right For decades, cardiovascular prevention was essentially a story about cholesterol. Yet a significant proportion of patients experience adverse events despite optimally controlled lipid levels—a reflection of a residual risk that...… CME-Test
View Post 4 min This content is machine translated SwissDiab Study: New Analysis Published How are diabetes complications associated with quality of life? The Swiss Diabetes Registry (SwissDiab) is a multicenter, national observational study and patient registry that collects data on complications in adults with diabetes mellitus in Switzerland. A recent analysis published...…
View Post 13 min This content is machine translated Obesity Treatment Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward Injectable GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless,...…
